论文部分内容阅读
目的:对低分子肝素钠治疗心肌梗死的临床疗效进行评价。方法:选择我院2014年9月至2015年9月收治的62例心肌梗死患者实行对比分析,分成31例的研究组和对照组分别采用常规治疗和低分子肝素钠治疗,并对比两组的临床疗效。结果:研究组的治疗总有效率为90.32%,与对照组的64.52%相比效果更佳,且P<0.05;对患者实行随访过程中发现,研究组经治疗后1个月、2个月还有3个月出现的复发情况均少于对照组,且后两个月的复发率对比下,二者组间比较差异P<0.05。结论:低分子肝素钠治疗心肌梗死的临床疗效显著,且患者出现复发情况较少,值得推广。
Objective: To evaluate the clinical efficacy of low molecular weight heparin in the treatment of myocardial infarction. Methods: Sixty-two patients with myocardial infarction who were treated in our hospital from September 2014 to September 2015 were compared and analyzed. The study group and the control group were divided into three groups: conventional treatment and low-molecular-weight heparin sodium treatment respectively. Clinical efficacy. Results: The total effective rate of the study group was 90.32%, which was better than that of the control group (64.52%), P <0.05. During the follow-up of the patients, the study group found that after 1 month and 2 months There was also less recurrence in 3 months than in control group, and the relapse rate in the last two months was compared with the difference between the two groups (P <0.05). Conclusion: The clinical efficacy of low molecular weight heparin in the treatment of myocardial infarction was significant, and the recurrence of patients with less, it is worth promoting.